<p>資產管理一號有限公司在最近向證券交易委員會提交的文件中表示，在第四季度其在雅培（NYSE:ABT - 免費報告）股票中的持股增加了 8.4%。該公司在此期間額外購買了 60,871 股後，持有 781,611 股該醫療產品製造商的股票。根據其最近的 SEC 文件，資產管理一號有限公司在雅培的持股價值為 89,877,000 美元。</p>
<p>獲取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>雅培將在 2025 年表現優於醫療股票</li>
</ul>
<p>其他機構投資者和對沖基金也對該公司的持倉進行了調整。Insight Folios Inc 在第三季度將其在雅培的持股增加了 3.3%。Insight Folios Inc 現在擁有 2,691 股該醫療產品製造商的股票，價值 307,000 美元，此前在上個季度額外購買了 87 股。Sfmg LLC 在第三季度將其在雅培的持股增加了 1.9%。Sfmg LLC 現在擁有 4,622 股該醫療產品製造商的股票，價值 527,000 美元，此前在此期間額外購買了 88 股。River Street Advisors LLC 在第四季度將其在雅培的持股增加了 1.2%。River Street Advisors LLC 現在擁有 7,370 股該醫療產品製造商的股票，價值 834,000 美元，此前在上個季度額外購買了 88 股。Wedge Capital Management L L P NC 在第三季度將其在雅培的持股增加了 2.9%。Wedge Capital Management L L P NC 現在擁有 3,153 股該醫療產品製造商的股票，價值 359,000 美元，此前在此期間額外購買了 89 股。最後，硅谷資本合夥公司在第三季度將其在雅培的持股增加了 8.7%。硅谷資本合夥公司現在擁有 1,108 股該醫療產品製造商的股票，價值 126,000 美元，此前在此期間額外購買了 89 股。目前 75.18% 的股票由機構投資者和對沖基金持有。</p>
<h2>內部買賣</h2>
<p>在其他消息中，執行副總裁 Daniel Gesua Sive Salvadori 於 1 月 30 日星期四出售了 23,771 股雅培股票。該股票以每股 128.50 美元的平均價格出售，總交易額為 3,054,573.50 美元。交易後，該執行副總裁現在直接持有 125,697 股公司股票，價值約為 16,152,064.50 美元。這筆交易代表其持倉減少了 15.90%。該出售在向證券交易委員會提交的文件中披露，可以通過此鏈接訪問。公司內部人士持有公司股票的 1.10%。</p>
<h2>華爾街分析師觀點</h2>
<ul>
<li>這些是值得長期投資的頂級醫療股票</li>
</ul>
<p>最近，一些分析師對 ABT 股票發表了看法。Piper Sandler 將雅培股票的目標價從 131.00 美元上調至 133.00 美元，並在 10 月 17 日的研究報告中給予該股票 “超配” 評級。StockNews.com 在週三的研究報告中將雅培的評級從 “強力買入” 下調至 “買入”。巴克萊在 1 月 27 日的報告中重申了 “超配” 評級，並將雅培股票的目標價上調至 158.00 美元（之前為 149.00 美元）。瑞穗證券在 10 月 17 日的研究報告中將雅培股票的目標價從 115.00 美元上調至 130.00 美元，並給予公司 “中性” 評級。最後，Stifel Nicolaus 在 1 月 23 日的研究報告中將雅培股票的目標價從 130.00 美元上調至 135.00 美元，並給予公司 “買入” 評級。四位投資分析師對該股票給予持有評級，十四位給予買入評級，一位給予強力買入評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，平均目標價為 133.06 美元。</p>
<p><strong>查看我們關於 ABT 的最新報告</strong></p>
<h2>雅培股票表現</h2>
<ul>
<li>MarketBeat 週迴顧 – 10/14 - 10/18</li>
</ul>
<p>ABT 股票在週五開盤價為 131.83 美元。該公司的市值為 2286.6 億美元，市盈率為 17.23，市盈增長比率為 2.39，貝塔值為 0.75。該股票的 50 日簡單移動平均為 118.34 美元，200 日簡單移動平均為 115.71 美元。該公司的流動比率為 1.60，速動比率為 1.14，債務與股本比率為 0.32。雅培的 12 個月低點為 99.71 美元，12 個月高點為 132.50 美元。</p>
<p>雅培（NYSE:ABT - 獲取免費報告）最近於 1 月 22 日星期三發佈了季度財報。該醫療產品製造商報告的每股收益（EPS）為 1.34 美元，符合分析師一致預期的 1.34 美元。雅培的股本回報率為 20.74%，淨利潤率為 31.95%。該公司在本季度的收入為 109.7 億美元，而分析師預期為 110.3 億美元。在去年同期，該公司發佈的每股收益為 1.19 美元。該公司的季度收入較去年同期增長了 7.2%。整體來看，股票研究分析師預測雅培在當前年度的每股收益將達到 5.14 美元。</p>
<h2>雅培增加股息</h2>
<p>該公司最近還宣佈了一項季度股息，將於 2 月 14 日星期五支付。1 月 15 日星期三的股東將獲得每股 0.59 美元的股息。這相當於年化股息為 2.36 美元，股息收益率為 1.79%。這比雅培之前的季度股息 0.55 美元有所增加。除息日期為 1 月 15 日星期三。雅培的股息支付比率（DPR）為 30.85%。</p>
<h2>雅培公司簡介</h2>
<p>（免費報告）</p>
<p>雅培及其子公司在全球範圍內發現、開發、製造和銷售醫療保健產品。它分為四個業務板塊：成熟藥品、診斷產品、營養產品和醫療器械。該公司提供用於治療胰腺外分泌功能不全、腸易激綜合症或膽道痙攣、肝內膽汁淤積或抑鬱症狀、婦科疾病、激素替代療法、血脂異常、高血壓、甲狀腺功能減退、梅尼埃病和前庭性眩暈、疼痛、發熱、炎症和偏頭痛的仿製藥，以及提供抗感染藥物克拉黴素、流感疫苗和調節結腸生理節律的產品。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票超過雅培</li>
<li>什麼是成長股及其投資</li>
<li>Upstart 的上升趨勢剛剛開始：是時候加倉了</li>
<li>如何投資 FAANG 股票</li>
<li>Archer Aviation 獲得黑石投資——ACHR 的下一步是什麼？</li>
<li>什麼是澳大利亞證券交易所（ASX）</li>
<li>巴菲特增持西方石油——堅持他的投資策略</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 嗎？</h2>
<p>在你進行下一筆交易之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。</p>
<p>我們的團隊已識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦在更廣泛的市場注意到之前購買……而且沒有大名鼎鼎的股票在名單上。</p>
<p>他們認為這五隻股票是投資者現在購買的五家最佳公司……</p>
<p>查看這五隻股票</p>
<h2>你現在應該投資$1,000 在雅培嗎？</h2>
<p>在你考慮雅培之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦在更廣泛的市場注意到之前購買……而雅培不在名單上。</p>
<p>雖然雅培目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

雅培

<p>資產管理一號有限公司在第四季度將其在雅培（NYSE:ABT）的持股增加了 8.4%，目前持有 781,611 股，價值為 8988 萬美元。其他機構投資者也調整了他們的持倉。執行副總裁 Daniel Gesua Sive Salvadori 出售了 23,771 股，減少了 15.90% 的持股比例。分析師對 ABT 的評級不一，平均目標價為 133.06 美元。該股票開盤價為 131.83 美元，市值為 2286.6 億美元，市盈率為 17.23</p>

<p>Asset Management One Co. Ltd. grew its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 8.4% in the 4th quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The firm owned 781,611 shares of the healthcare product maker's stock after buying an additional 60,871 shares during the period. Asset Management One Co. Ltd.'s holdings in Abbott Laboratories were worth $89,877,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>資產管理一號有限公司在最近向證券交易委員會提交的文件中表示，在第四季度其在雅培（NYSE:ABT - 免費報告）股票中的持股增加了 8.4%。該公司在此期間額外購買了 60,871 股後，持有 781,611 股該醫療產品製造商的股票。根據其最近的 SEC 文件，資產管理一號有限公司在雅培的持股價值為 89,877,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>Abbott Laboratories Will Outperform Healthcare Stocks in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培將在 2025 年表現優於醫療股票</li>
</ul>
</div><p>Other institutional investors and hedge funds have also made changes to their positions in the company. Insight Folios Inc increased its stake in Abbott Laboratories by 3.3% during the third quarter. Insight Folios Inc now owns 2,691 shares of the healthcare product maker's stock worth $307,000 after acquiring an additional 87 shares during the last quarter. Sfmg LLC raised its holdings in Abbott Laboratories by 1.9% in the third quarter. Sfmg LLC now owns 4,622 shares of the healthcare product maker's stock valued at $527,000 after buying an additional 88 shares during the period. River Street Advisors LLC lifted its position in Abbott Laboratories by 1.2% during the fourth quarter. River Street Advisors LLC now owns 7,370 shares of the healthcare product maker's stock valued at $834,000 after buying an additional 88 shares in the last quarter. Wedge Capital Management L L P NC grew its stake in Abbott Laboratories by 2.9% during the third quarter. Wedge Capital Management L L P NC now owns 3,153 shares of the healthcare product maker's stock worth $359,000 after buying an additional 89 shares during the period. Finally, Silicon Valley Capital Partners raised its stake in shares of Abbott Laboratories by 8.7% in the 3rd quarter. Silicon Valley Capital Partners now owns 1,108 shares of the healthcare product maker's stock valued at $126,000 after acquiring an additional 89 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金也對該公司的持倉進行了調整。Insight Folios Inc 在第三季度將其在雅培的持股增加了 3.3%。Insight Folios Inc 現在擁有 2,691 股該醫療產品製造商的股票，價值 307,000 美元，此前在上個季度額外購買了 87 股。Sfmg LLC 在第三季度將其在雅培的持股增加了 1.9%。Sfmg LLC 現在擁有 4,622 股該醫療產品製造商的股票，價值 527,000 美元，此前在此期間額外購買了 88 股。River Street Advisors LLC 在第四季度將其在雅培的持股增加了 1.2%。River Street Advisors LLC 現在擁有 7,370 股該醫療產品製造商的股票，價值 834,000 美元，此前在上個季度額外購買了 88 股。Wedge Capital Management L L P NC 在第三季度將其在雅培的持股增加了 2.9%。Wedge Capital Management L L P NC 現在擁有 3,153 股該醫療產品製造商的股票，價值 359,000 美元，此前在此期間額外購買了 89 股。最後，硅谷資本合夥公司在第三季度將其在雅培的持股增加了 8.7%。硅谷資本合夥公司現在擁有 1,108 股該醫療產品製造商的股票，價值 126,000 美元，此前在此期間額外購買了 89 股。目前 75.18% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In other news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of Abbott Laboratories stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the transaction, the executive vice president now directly owns 125,697 shares in the company, valued at approximately $16,152,064.50. This trade represents a 15.90 % decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Corporate insiders own 1.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，執行副總裁 Daniel Gesua Sive Salvadori 於 1 月 30 日星期四出售了 23,771 股雅培股票。該股票以每股 128.50 美元的平均價格出售，總交易額為 3,054,573.50 美元。交易後，該執行副總裁現在直接持有 125,697 股公司股票，價值約為 16,152,064.50 美元。這筆交易代表其持倉減少了 15.90%。該出售在向證券交易委員會提交的文件中披露，可以通過此鏈接訪問。公司內部人士持有公司股票的 1.10%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><ul>
<li>These Are The Top Health Stocks to Own for Buy-and-Hold Investing</li>
</ul>
<div class="lb-trans"><ul>
<li>這些是值得長期投資的頂級醫療股票</li>
</ul>
</div><p>A number of analysts recently weighed in on ABT shares. Piper Sandler upped their price target on shares of Abbott Laboratories from $131.00 to $133.00 and gave the stock an &#34;overweight&#34; rating in a research report on Thursday, October 17th. StockNews.com lowered Abbott Laboratories from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Wednesday. Barclays restated an &#34;overweight&#34; rating and issued a $158.00 price target (up previously from $149.00) on shares of Abbott Laboratories in a report on Monday, January 27th. Mizuho lifted their price objective on shares of Abbott Laboratories from $115.00 to $130.00 and gave the company a &#34;neutral&#34; rating in a research note on Thursday, October 17th. Finally, Stifel Nicolaus upped their target price on shares of Abbott Laboratories from $130.00 to $135.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, January 23rd. Four investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $133.06.</p>
<div class="lb-trans"><p>最近，一些分析師對 ABT 股票發表了看法。Piper Sandler 將雅培股票的目標價從 131.00 美元上調至 133.00 美元，並在 10 月 17 日的研究報告中給予該股票 “超配” 評級。StockNews.com 在週三的研究報告中將雅培的評級從 “強力買入” 下調至 “買入”。巴克萊在 1 月 27 日的報告中重申了 “超配” 評級，並將雅培股票的目標價上調至 158.00 美元（之前為 149.00 美元）。瑞穗證券在 10 月 17 日的研究報告中將雅培股票的目標價從 115.00 美元上調至 130.00 美元，並給予公司 “中性” 評級。最後，Stifel Nicolaus 在 1 月 23 日的研究報告中將雅培股票的目標價從 130.00 美元上調至 135.00 美元，並給予公司 “買入” 評級。四位投資分析師對該股票給予持有評級，十四位給予買入評級，一位給予強力買入評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，平均目標價為 133.06 美元。</p>
</div><p><strong>View Our Latest Report on ABT</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 ABT 的最新報告</strong></p>
</div><h2>Abbott Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>雅培股票表現</h2>
</div><ul>
<li>MarketBeat Week in Review – 10/14 - 10/18</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 10/14 - 10/18</li>
</ul>
</div><p>ABT stock opened at $131.83 on Friday. The firm has a market cap of $228.66 billion, a P/E ratio of 17.23, a P/E/G ratio of 2.39 and a beta of 0.75. The stock's 50 day simple moving average is $118.34 and its 200 day simple moving average is $115.71. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $132.50.</p>
<div class="lb-trans"><p>ABT 股票在週五開盤價為 131.83 美元。該公司的市值為 2286.6 億美元，市盈率為 17.23，市盈增長比率為 2.39，貝塔值為 0.75。該股票的 50 日簡單移動平均為 118.34 美元，200 日簡單移動平均為 115.71 美元。該公司的流動比率為 1.60，速動比率為 1.14，債務與股本比率為 0.32。雅培的 12 個月低點為 99.71 美元，12 個月高點為 132.50 美元。</p>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business had revenue of $10.97 billion during the quarter, compared to analyst estimates of $11.03 billion. During the same quarter in the previous year, the firm posted $1.19 EPS. The business's revenue for the quarter was up 7.2% compared to the same quarter last year. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 獲取免費報告）最近於 1 月 22 日星期三發佈了季度財報。該醫療產品製造商報告的每股收益（EPS）為 1.34 美元，符合分析師一致預期的 1.34 美元。雅培的股本回報率為 20.74%，淨利潤率為 31.95%。該公司在本季度的收入為 109.7 億美元，而分析師預期為 110.3 億美元。在去年同期，該公司發佈的每股收益為 1.19 美元。該公司的季度收入較去年同期增長了 7.2%。整體來看，股票研究分析師預測雅培在當前年度的每股收益將達到 5.14 美元。</p>
</div><h2>Abbott Laboratories Increases Dividend</h2>
<div class="lb-trans"><h2>雅培增加股息</h2>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be issued a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.79%. This is a positive change from Abbott Laboratories's previous quarterly dividend of $0.55. The ex-dividend date is Wednesday, January 15th. Abbott Laboratories's dividend payout ratio (DPR) is 30.85%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度股息，將於 2 月 14 日星期五支付。1 月 15 日星期三的股東將獲得每股 0.59 美元的股息。這相當於年化股息為 2.36 美元，股息收益率為 1.79%。這比雅培之前的季度股息 0.55 美元有所增加。除息日期為 1 月 15 日星期三。雅培的股息支付比率（DPR）為 30.85%。</p>
</div><h2>Abbott Laboratories Profile</h2>
<div class="lb-trans"><h2>雅培公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p>
<div class="lb-trans"><p>雅培及其子公司在全球範圍內發現、開發、製造和銷售醫療保健產品。它分為四個業務板塊：成熟藥品、診斷產品、營養產品和醫療器械。該公司提供用於治療胰腺外分泌功能不全、腸易激綜合症或膽道痙攣、肝內膽汁淤積或抑鬱症狀、婦科疾病、激素替代療法、血脂異常、高血壓、甲狀腺功能減退、梅尼埃病和前庭性眩暈、疼痛、發熱、炎症和偏頭痛的仿製藥，以及提供抗感染藥物克拉黴素、流感疫苗和調節結腸生理節律的產品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>What Are Growth Stocks and Investing in Them</li>
<li>Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up</li>
<li>How to Invest in the FAANG Stocks</li>
<li>Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?</li>
<li>What is the Australian Securities Exchange (ASX)</li>
<li>Buffett Buys More Occidental Petroleum—Sticking to His Playbook</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過雅培</li>
<li>什麼是成長股及其投資</li>
<li>Upstart 的上升趨勢剛剛開始：是時候加倉了</li>
<li>如何投資 FAANG 股票</li>
<li>Archer Aviation 獲得黑石投資——ACHR 的下一步是什麼？</li>
<li>什麼是澳大利亞證券交易所（ASX）</li>
<li>巴菲特增持西方石油——堅持他的投資策略</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Where Should You Invest $1,000 Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 嗎？</h2>
</div><p>Before you make your next trade, you'll want to hear this.</p>
<div class="lb-trans"><p>在你進行下一筆交易之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。</p>
</div><p>Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.</p>
<div class="lb-trans"><p>我們的團隊已識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦在更廣泛的市場注意到之前購買……而且沒有大名鼎鼎的股票在名單上。</p>
</div><p>They believe these five stocks are the five best companies for investors to buy now...</p>
<div class="lb-trans"><p>他們認為這五隻股票是投資者現在購買的五家最佳公司……</p>
</div><p>See The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在雅培嗎？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮雅培之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦在更廣泛的市場注意到之前購買……而雅培不在名單上。</p>
</div><p>While Abbott Laboratories currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然雅培目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

資產管理一號有限公司購買了雅培（紐約證券交易所代碼：ABT）的股票